PROC and Sepsis: A secondary analysis of the “A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis” (ACCESS) trial and the “Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis” (PROWESS)-SHOCK trial found that of those surviving after treatment for severe sepsis, 33.1% and 34.3% had not returned to independent living by 6 months, respectively [4–6].